Insider Transactions in Q2 2022 at Lexicon Pharmaceuticals, Inc. (LXRX)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 30
2022
|
Philippe Amouyal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|
|
Apr 30
2022
|
Sam L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+5.41%
|
-
|
|
Apr 30
2022
|
Raymond Debbane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+1.2%
|
-
|
|
Apr 30
2022
|
Robert J Md Lefkowitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|
|
Apr 30
2022
|
Alan S Nies Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.25%
|
-
|
|
Apr 30
2022
|
Frank Palantoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|
|
Apr 30
2022
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+2.62%
|
-
|
|
Apr 30
2022
|
Judith L Swain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,024
+11.48%
|
-
|